Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on November 13, 2025. The filing serves to disclose the issuance of a press release regarding financial results for the third quarter ended September 30, 2025, and recent corporate developments.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were announced in a press release (Exhibit 99.1) but does not reproduce the financial data within the 8-K body text.
Material Changes
No specific material changes versus the prior comparable period are detailed in this filing text. The report indicates that such information is contained within the referenced press release.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release containing management commentary and corporate developments. The document explicitly states that the information furnished under Item 2.02 and Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated. No specific risks, contingencies, or unusual items are described in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2025) for actual Q3 2025 financial figures.
- Verify the specific details of "recent corporate developments" mentioned in the press release.
- Confirm the company's cash runway and burn rate, as these are not listed in the 8-K summary text.
- Check for any updated clinical trial milestones or regulatory status updates included in the referenced press release.